Printed from Voxsanity (voxsanity.com.au) — NCT06158841 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who are reasonably active and able to carry out daily activities (as measured by a standard health performance scale, scored 0–2)
People who have been diagnosed with multiple myeloma that has come back or stopped responding to treatment
People whose myeloma can be detected through specific blood or urine tests, measured within 28 days of joining the trial (confirm with trial site for exact test thresholds)
People who have already tried at least 2 previous myeloma treatments (or at least 1 for those in the US or Puerto Rico), which must have included three specific types of therapy: a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody treatment
People for whom a doctor determines that a standard approved myeloma treatment is appropriate based on their treatment history and medical guidelines
Who may not be able to join:
People who have had a significant problem with drug or alcohol use in the past 6 months
People who have had a serious condition affecting the nervous system, mental health, hormones, immune system, heart, lungs, or liver in the past 6 months, where that condition could affect safe participation in the study
People whose multiple myeloma has spread to the central nervous system (brain or spinal cord)
People who have previously received a treatment that targets a protein called BCMA (B-cell maturation antigen)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
St George Hospital - Kogarah /ID# 261806, Kogarah, New South Wales
Liverpool Hospital /ID# 262159, Liverpool, New South Wales
Calvary Mater Newcastle /ID# 261804, Waratah, New South Wales
Princess Alexandra Hospital - Woolloongabba /ID# 261810, Woolloongabba, Queensland
Monash Health - Monash Medical Centre - Clayton /ID# 262158, Clayton, Victoria
St Vincent's Hospital Melbourne /ID# 261808, Fitzroy Melbourne, Victoria
Box Hill Hospital /ID# 262784, Melbourne, Victoria
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT06158841
Sponsor: AbbVie
Phase: Phase 3
Status: Recruiting
Condition: Myeloma
Trial contact: 844-663-3742
More information: https://clinicaltrials.gov/study/NCT06158841
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who are reasonably active and able to carry out daily activities (as measured by a standard health performance scale, scored 0–2)
People who have been diagnosed with multiple myeloma that has come back or stopped responding to treatment
People whose myeloma can be detected through specific blood or urine tests, measured within 28 days of joining the trial (confirm with trial site for exact test thresholds)
People who have already tried at least 2 previous myeloma treatments (or at least 1 for those in the US or Puerto Rico), which must have included three specific types of therapy: a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody treatment
People for whom a doctor determines that a standard approved myeloma treatment is appropriate based on their treatment history and medical guidelines
Who may not be able to join:
People who have had a significant problem with drug or alcohol use in the past 6 months
People who have had a serious condition affecting the nervous system, mental health, hormones, immune system, heart, lungs, or liver in the past 6 months, where that condition could affect safe participation in the study
People whose multiple myeloma has spread to the central nervous system (brain or spinal cord)
People who have previously received a treatment that targets a protein called BCMA (B-cell maturation antigen)
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
🇦🇺 Australia
🇦🇹 Austria
🇧🇪 Belgium
🇨🇦 Canada
🇨🇳 China
🇨🇿 Czechia
🇩🇰 Denmark
🇫🇷 France
🇩🇪 Germany
🇬🇷 Greece
🇭🇺 Hungary
🇮🇱 Israel
🇮🇹 Italy
🇯🇵 Japan
🇵🇱 Poland
🇵🇹 Portugal
Puerto Rico
🇿🇦 South Africa
🇰🇷 South Korea
🇪🇸 Spain
🇸🇪 Sweden
🇹🇼 Taiwan
Turkey (Türkiye)
🇬🇧 United Kingdom
🇺🇸 United States
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.